VGX-100 is a human antibody that acts against the human VEGF-C protein.
VGX-100 when combined with Avastin and chemotherapy, demonstrated reduced tumour growth and tumour spread, and improved tumour inhibition, in animal models.
The Phase I study will evaluate VGX-100 in patients with a variety of late stage cancers.
Circadian Technologies CEO Robert Klupacs said the company expects to start clinical trials before the end of 2011, with results to be available in the second half of 2012.